NOX Insider Trading

Insider Ownership Percentage: 35.21%
Insider Buying (Last 12 Months): A$9,108.04
Insider Selling (Last 12 Months): A$0.00

Noxopharm Insider Trading History Chart

This chart shows the insider buying and selling history at Noxopharm by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Noxopharm Share Price & Price History

Current Price: A$0.00
Price Change: +0.30 (1.20%)
As of 05/13/2020 01:00 AM ET

This chart shows the closing price history over time for NOX up to the past year.

Skip Chart and Table DataPrice Data in Insider Trading History Table

Noxopharm Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
9/14/2023Frederick (Fred) BartInsiderBuy253,001A$0.04A$9,108.04
6/29/2023Frederick (Fred) BartInsiderTransfer3,080,189A$0.06A$169,410.40
5/9/2023Frederick (Fred) BartInsiderBuy500,000A$0.04A$21,000.00
5/4/2023Frederick (Fred) BartInsiderBuy1,000,000A$0.05A$50,000.00
12/15/2022Frederick (Fred) BartInsiderExpiry3,000,000A$0.15A$435,000.00
12/1/2021Graham KellyInsiderExpiry37,037A$0.44A$16,296.28
See Full Table

SEC Filings (Institutional Ownership Changes) for Noxopharm (ASX:NOX)

Noxopharm logo
Noxopharm Limited, a biotech company, discovers and develops treatments for cancer and inflammation, and mRNA vaccines in Australia. It primarily develops Veyonda, a formulation of idronoxil for the treatment of solid tumors. The company also develops LuPIN with combined therapy of Veyonda and 177Lu-PSMA-617 for the treatment of late-stage prostate cancer; and IONIC program with Veyonda, which is combined with the Bristol Myers Squibb checkpoint inhibitor Opdivo for the treatment of various solid tumor types. In addition, it develops NOXCOVID Program, a dose escalation and dose expansion study of NOX66 for the treatment of COVID-19 infection. Further, the company develops Chroma technology platform to develop CRO-67 dual-cell therapy drug for the treatment of pancreatic cancer and various molecules for the treatment of autoimmune disease and hyperinflammatory conditions; and Sofra platform that focuses on the development of immunomodulators for mRNA vaccines and mRNA therapeutics, as well as for the treatment of autoimmune diseases. The company was incorporated in 2015 and is based in Glenhaven, Australia.
Read More on Noxopharm

Today's Range

Now: N/A

50 Day Range


52 Week Range

Now: N/A


1,231,749 shs

Average Volume


Market Capitalization


P/E Ratio


Dividend Yield




Who are the company insiders with the largest holdings of Noxopharm?

Noxopharm's top insider shareholders include:
  1. Frederick (Fred) Bart (Insider)
Learn More about top insider investors at Noxopharm.